Meta-analysis on goserelin in protection of ovarian function in premenopausal patients with breast cancer
Objective To evaluate the ability of goserelin in the protection of the ovarian function in premenopausal patients with breast cancer by meta-analysis.Methods The China National Knowledge Infrastructure,Wanfang Database,VIP Database,PubMed,Web of Science,Scopus,and Cochrane Library were searched for the controlled trials of goserelin for premenopausal patients with breast cancer from their establishment to October 2023.Two investigators independently screened the literatures according to the inclusion and exclusion criteria,extracted the data,and evaluated the quality of the included studies using the Cochrane Collaboration risk of bias assessment tool.The data were analyzed using the RevMan 5.3 software.Results Twenty-eight studies and 8 782 patients were included,including 4 372 in the test group and 4 410 in the control group.The meta-analysis results showed that the total effective rate of the test group was higher than that of the control group(OR=2.87,95％CI 1.94-4.26,P＜0.000 01);the basal follicle-stimulating hormone(bFSH)level of the test group was lower than that of the control group(MD=-3.81,95％CI-4.35 to-3.27,P＜0.000 01);the basal antral follicle counting(bAFC)of the test group was higher than that of the control group(MD=3.27,95％CI 2.83-3.72,P＜0.000 01);the estradiol(E2)level in the test group was not significantly different from that in the control group(SMD=0.85,95％CI-0.69 to-2.40,P=0.28);the luteinizing hormone(LH)in the test group was higher than that in the control group(MD=8.75,95％CI 7.84-9.67,P＜0.000 01);the premature ovarian failure(POI)in the test group was lower than that in the control group(OR=0.24,95％CI 0.08-0.73,P=0.01);the menstrual recurrence rate in the test group was higher than that in the control group(OR=3.09,95％CI 1.01-9.46,P=0.05);the disease-free survival(DFS)in the test group was higher than that in the control group(OR=1.91,95％CI1.28-2.85,P=0.002);the overall survival(OS)in the test group was higher than that in the control group(OR=1.35,95％CI 1.14-1.59,P=0.000 4);the progression-free-survival(PFS)in the test group was higher than that in the control group(MD=30.15,95％CI 29.47-30.83,P＜0.000 01);the incidence of adverse reactions in the test group was lower than that in the control group(OR=0.48,95％CI 0.25-0.90,P=0.02).Conclusion Goserelin for premenopausal patients with breast cancer effectively protects their ovarian function and improves their survival time,and is safe.
GoserelinPremenopausal breast cancerOvarian functionMeta-analysis
万方数据
维普
